Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2017 Filed Jul 22, 2017 01:45 UTC |
Cumbo AlexanderSVP, Chief Commercial Officer
|
Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 2,500 | $13.71 Strike: $13.71 | $34,275.00 |
DisclosureSEC source: 0001209191-17-046035 · doc4.xml · derivative · entry 4 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,774 Underlying: Common Stock · 2,500 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:45 UTC |
Cumbo AlexanderSVP, Chief Commercial Officer
|
SaleCommon Stock | 3,418 | $41.00 | $140,138.00 |
DisclosureSEC source: 0001209191-17-046035 · doc4.xml · nonDerivative · entry 3 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:45 UTC |
Cumbo AlexanderSVP, Chief Commercial Officer
|
SaleCommon Stock | 2,500 | $41.00 | $102,500.00 |
DisclosureSEC source: 0001209191-17-046035 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,293 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:45 UTC |
Cumbo AlexanderSVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 2,500 | $13.71 | $34,275.00 |
DisclosureSEC source: 0001209191-17-046035 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:50 UTC |
INGRAM DOUGLAS SDirector · President & CEO
|
GrantStock Option (right to buy) · Derivative | 3,300,000 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001209191-17-042164 · doc4.xml · derivative · entry 2 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300,000 Underlying: Common Stock · 3,300,000 shares Expires 2027-06-26 F2 · derivative.exercise_date: On June 26, 2022, subject to the Reporting Person's continued service to the Issuer or a subsidiary thereof from the date of grant through such date, a percentage of the stock options will vest based on the extent to which the compounded annual growth rate ("CAGR") of the Issuer's stock price from June 26, 2017 (based on the closing price on such date) through June 26, 2022 (based on the average of the closing price of the Issuer's common stock on the 20 days immediately preceding such date) exceeds the CAGR of the NASDAQ Biotech Index (or any successor index) during the same period. F3 · derivative.expiration_date: In certain situations, the stock options will expire within twelve months of such situation, but in no event will the stock options be exercisable after June 26, 2027. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:50 UTC |
INGRAM DOUGLAS SDirector · President & CEO
|
GrantCommon Stock | 335,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042164 · doc4.xml · nonDerivative · entry 1 INGRAM DOUGLAS S · CIK 0001190644 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 F1 · shares: Represents shares of restricted stock. Twenty-five percent of the shares will vest on June 26, 2018 and one thirty-sixth of the remaining unvested shares will vest on each monthly anniversary of June 26 thereafter, ending on June 26, 2021, in each case subject to the Reporting Person's continued service to the Issuer or a subsidiary thereof from the date of grant through each applicable vesting date. Read SEC document |
| May 19, 2017 Filed Jun 8, 2017 12:33 UTC |
Cumbo AlexanderSVP, Chief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $34.64 | $0.00 |
DisclosureSEC source: 0001209191-17-038455 · doc4.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-05-19 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 21:11 UTC |
Kaye Edward M. MDDirector · President & CEO
|
Tax withholdingCommon Stock | 4,349 | $32.54 | $141,516.46 |
DisclosureSEC source: 0001209191-17-027998 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,820 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 21:06 UTC |
Stehman-Breen CatherineSVP, Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-17-025720 · doc4.xml · derivative · entry 1 Stehman-Breen Catherine · CIK 0001702233 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-04-03 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 19, 2017 Filed Mar 21, 2017 22:05 UTC |
Mahatme SandeshEVP, CFO & CBO
|
Tax withholdingCommon Stock | 171 | $30.30 | $5,181.30 |
DisclosureSEC source: 0001209191-17-022109 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,361 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock granted on 9/19/2016. Read SEC document |
| March 19, 2017 Filed Mar 21, 2017 22:07 UTC |
Howton David TSVP, General Counsel
|
Tax withholdingCommon Stock | 152 | $30.30 | $4,605.60 |
DisclosureSEC source: 0001209191-17-022110 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,301 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock granted on 9/19/2016. Read SEC document |
| March 19, 2017 Filed Mar 21, 2017 22:01 UTC |
Ruff ShamimSVP, Regulatory Affairs & Qual
|
Tax withholdingCommon Stock | 177 | $30.30 | $5,363.10 |
DisclosureSEC source: 0001209191-17-022104 · doc4.xml · nonDerivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,062 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock granted on 9/19/2016. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:48 UTC |
Mahatme SandeshEVP, CFO & CBO
|
GrantIncentive Stock Option (right to buy) · Derivative | 4,751 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020689 · doc4.xml · derivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,751 Underlying: Common Stock · 4,751 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:48 UTC |
Mahatme SandeshEVP, CFO & CBO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 32,749 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020689 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,749 Underlying: Common Stock · 32,749 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:51 UTC |
Cumbo AlexanderVP, Head of Commercial
|
GrantIncentive Stock Option (right to buy) · Derivative | 4,924 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020692 · doc4.xml · derivative · entry 2 Cumbo Alexander · CIK 0001685994 · VP, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,924 Underlying: Common Stock · 4,924 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:51 UTC |
Cumbo AlexanderVP, Head of Commercial
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 22,576 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020692 · doc4.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · VP, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,576 Underlying: Common Stock · 22,576 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:50 UTC |
Ruff ShamimSVP, Regulatory Affairs & Qual
|
GrantIncentive Stock Option (right to buy) · Derivative | 4,189 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020691 · doc4.xml · derivative · entry 2 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,189 Underlying: Common Stock · 4,189 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:50 UTC |
Ruff ShamimSVP, Regulatory Affairs & Qual
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,811 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020691 · doc4.xml · derivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,811 Underlying: Common Stock · 20,811 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:49 UTC |
Howton David TSVP, General Counsel
|
GrantIncentive Stock Option (right to buy) · Derivative | 4,411 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020690 · doc4.xml · derivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,411 Underlying: Common Stock · 4,411 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:49 UTC |
Howton David TSVP, General Counsel
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,589 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020690 · doc4.xml · derivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,589 Underlying: Common Stock · 25,589 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:47 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
GrantIncentive Stock Option (right to buy) · Derivative | 4,377 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020688 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,377 Underlying: Common Stock · 4,377 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:47 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 95,623 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020688 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,623 Underlying: Common Stock · 95,623 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:46 UTC |
Nicaise ClaudeDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020686 · doc4.xml · derivative · entry 2 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:46 UTC |
Nicaise ClaudeDirector
|
GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020686 · doc4.xml · nonDerivative · entry 1 Nicaise Claude · CIK 0001644162 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:46 UTC |
Wigzell Hans Lennart RudolfDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020687 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:46 UTC |
Wigzell Hans Lennart RudolfDirector
|
GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020687 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:45 UTC |
BEHRENS M KATHLEENDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020685 · doc4.xml · derivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:45 UTC |
BEHRENS M KATHLEENDirector
|
GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020685 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,116 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:37 UTC |
BEHRENS M KATHLEENDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020682 · doc4.xml · derivative · entry 2 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:37 UTC |
BEHRENS M KATHLEENDirector
|
GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020682 · doc4.xml · nonDerivative · entry 1 BEHRENS M KATHLEEN · CIK 0001211701 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,116 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:27 UTC |
Barry RichardDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020680 · doc4.xml · derivative · entry 2 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:27 UTC |
Barry RichardDirector
|
GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020680 · doc4.xml · nonDerivative · entry 1 Barry Richard · CIK 0001562371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,242,014 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:42 UTC |
Kress Jean-PaulDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020684 · doc4.xml · derivative · entry 2 Kress Jean-Paul · CIK 0001654979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2027-03-10 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:42 UTC |
Kress Jean-PaulDirector
|
GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020684 · doc4.xml · nonDerivative · entry 1 Kress Jean-Paul · CIK 0001654979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of Sarepta's 2017 Annual Meeting of Stockholders. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:52 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
Tax withholdingCommon Stock | 4,466 | $32.66 | $145,859.56 |
DisclosureSEC source: 0001209191-17-005349 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,169 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:27 UTC |
Howton David TSVP, General Counsel
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-16-149230 · doc4.xml · derivative · entry 2 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,768 Underlying: Common Stock · 1,000 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the option granted became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:27 UTC |
Howton David TSVP, General Counsel
|
Exercise / conversionCommon Stock | 1,000 | $23.85 | $23,850.00 |
DisclosureSEC source: 0001209191-16-149230 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:26 UTC |
Mahatme SandeshSenior Vice President, CFO
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-16-149229 · doc4.xml · derivative · entry 2 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,768 Underlying: Common Stock · 1,000 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:26 UTC |
Mahatme SandeshSenior Vice President, CFO
|
Exercise / conversionCommon Stock | 1,000 | $23.85 | $23,850.00 |
DisclosureSEC source: 0001209191-16-149229 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:19 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001209191-16-149227 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,309 Underlying: Common Stock · 3,000 shares Expires 2021-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option became exercisable at the rate of 25% of the shares on June 20, 2012 and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option became fully exercisable on June 20, 2015. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:19 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
Exercise / conversionCommon Stock | 3,000 | $8.28 | $24,840.00 |
DisclosureSEC source: 0001209191-16-149227 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 13:20 UTC |
Ruff ShamimSVP, Regulatory Affairs & Qual
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $26.24 | $0.00 |
DisclosureSEC source: 0001209191-16-149228 · doc4.xml · derivative · entry 2 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,097 Underlying: Common Stock · 1,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the option became exercisable on the first anniversary of the date of hire (01/02/2013) and 1/48th of the total granted option becomes exercisable on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of hire. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 13:20 UTC |
Ruff ShamimSVP, Regulatory Affairs & Qual
|
Exercise / conversionCommon Stock | 1,000 | $26.24 | $26,240.00 |
DisclosureSEC source: 0001209191-16-149228 · doc4.xml · nonDerivative · entry 1 Ruff Shamim · CIK 0001685986 · SVP, Regulatory Affairs & Qual 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 20:33 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
Tax withholdingCommon Stock | 4,348 | $49.05 | $213,269.40 |
DisclosureSEC source: 0001209191-16-146739 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,635 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:22 UTC |
Mahatme SandeshSenior Vice President, CFO
|
Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 30,000 | $13.90 Strike: $13.90 | $417,000.00 |
DisclosureSEC source: 0001209191-16-146354 · doc4.xml · derivative · entry 3 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,874 Underlying: Common Stock · 30,000 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on September 15, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:22 UTC |
Mahatme SandeshSenior Vice President, CFO
|
SaleCommon Stock | 30,000 | $50.08 | $1,502,502.00 |
DisclosureSEC source: 0001209191-16-146354 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,532 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on September 15, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:22 UTC |
Mahatme SandeshSenior Vice President, CFO
|
Exercise / conversionCommon Stock | 30,000 | $13.90 | $417,000.00 |
DisclosureSEC source: 0001209191-16-146354 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on September 15, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:23 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 40,179 | $8.28 Strike: $13.90 | $332,682.12 |
DisclosureSEC source: 0001209191-16-142786 · doc4.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,179 Underlying: Common Stock · 40,179 shares Expires 2021-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:23 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
SaleCommon Stock | 40,179 | $60.00 | $2,410,740.00 |
DisclosureSEC source: 0001209191-16-142786 · doc4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,983 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:23 UTC |
Kaye Edward M. MDDirector · President, CEO & CMO
|
Exercise / conversionCommon Stock | 40,179 | $8.28 | $332,682.12 |
DisclosureSEC source: 0001209191-16-142786 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.